Skip to main content
GenMont logo

GenMont — Investor Relations & Filings

Ticker · 3164 ISIN · TW0003164000 TW Manufacturing
Open in API
Filings indexed 1,617 across all filing types
Latest filing 2019-08-09 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 3164

About GenMont

www.genmont.com.tw

GenMont Biotech Inc. specializes in the research, development, and manufacturing of functional probiotics and postbiotics. The company operates advanced fermentation and production platforms for concentrated fermented milk, lactic acid bacteria powders, and functional microorganism strains. Its product portfolio features patented probiotic solutions targeting diverse health areas, including immune modulation, metabolic health, dental hygiene, digestive function, weight management, and pet wellness. Key proprietary strains include L. paracasei 33 and GMNL-32. GenMont leverages its technology platforms and extensive patent portfolio to deliver scientifically-backed health supplements. Beyond its proprietary brands, the company provides original equipment manufacturing (OEM) services, supporting the global market with high-quality probiotic and postbiotic ingredients certified by international standards.

Recent filings

Filing Released Lang Actions
108年7月營業收入
Interim / Quarterly Report Classification · 90% confidence The document is a summarized revenue report for a company named 景岳, showing monthly and cumulative net operating revenue figures for a specific period (民國108年07月, which corresponds to July 2019). It includes percentage changes compared to the previous year and explanatory notes about accounting standards (IFRS) and reporting practices. The document is very short (770 characters) and primarily presents financial data for a single month and year-to-date, without detailed financial statements or management discussion. It is not an announcement of a report publication but a direct presentation of financial figures. Given the presence of substantive financial data for a period shorter than a full fiscal year (monthly and cumulative figures), this fits the definition of an Interim / Quarterly Report (IR). Q2 2019
2019-08-09 Chinese
107年年報及股東會資料 — 2018_3164_20190628F11.pdf
Annual Report Classification · 100% confidence The document is titled as the '107年度年報' which translates to the 'Year 107 Annual Report' (in the Taiwanese calendar, year 107 corresponds to 2018). It includes detailed sections such as shareholder reports, company governance, capital and shareholding information, operational overview, and financial overview including audited financial statements and auditor's reports. The length is substantial (15,000 characters) and contains comprehensive financial and operational data typical of a full annual report. There is no indication that this is merely an announcement or a summary, but rather the full annual report itself. FY 2018
2019-07-16 Chinese
107年年報及股東會資料 — 2019_3164_20190628F05.pdf
Annual Report Classification · 95% confidence The document is a detailed record of a shareholders' meeting held by 景岳生物科技股份有限公司, including attendance, agenda items, voting results, and attached reports such as the 107年度營業報告書 (Annual Business Report), 監察人審查報告 (Supervisors' Review Report), and 會計師查核報告書及107年度財務報表 (Auditor's Report and 2018 Financial Statements). The content includes comprehensive financial data, management discussion, auditor opinions, and formal approval of annual financial statements and profit distribution. The presence of detailed financial statements, audit reports, and management reports within the document indicates it is the full Annual Report rather than just an announcement or a summary. The document length (15,000 characters) and the inclusion of multiple attachments and detailed financial tables further support this classification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2018
2019-07-16 Chinese
107年年報及股東會資料 — 2019_3164_20190628F15.zip
Regulatory Filings
2019-07-16 Chinese
107年年報及股東會資料 — 2019_3164_20190628F14.pdf
Regulatory Filings Classification · 95% confidence The document is a detailed procedural guideline titled '景岳生物科技股份有限公司 取得或處分資產處理程序' which translates to 'Jingyue Biotechnology Co., Ltd. Procedures for Acquisition or Disposal of Assets.' It extensively references the Securities Exchange Act, regulations from the Financial Supervisory Commission, and covers detailed internal control procedures for asset acquisition and disposal, including real estate, securities, intangible assets, derivatives, and related party transactions. It also includes requirements for professional appraisals, board approvals, and disclosure obligations. The document is regulatory in nature, focusing on compliance and procedural rules rather than financial results or announcements. It does not contain financial statements, earnings data, or meeting results. It is not a report of financial performance, nor an announcement of voting results or management changes. It is a regulatory compliance document outlining internal procedures and legal requirements for asset transactions. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory and compliance documents that do not fit other specific categories.
2019-07-16 Chinese
107年年報及股東會資料 — 2019_3164_20190628F17.pdf
Major Shareholding Notification Classification · 100% confidence The document lists the top ten shareholders of the company 景岳生物科技股份有限公司 as of a specific date (April 30, 2019) and details their shareholdings and relationships among them. This type of information corresponds to a Major Shareholding Notification, which reports changes or status of significant share ownership levels. The document is not an announcement of a report, nor is it a full financial report or management information. It specifically focuses on shareholding data and relationships, fitting the Major Shareholding Notification category.
2019-07-16 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.